Calgary, Alberta — February 26, 2026 — Leads & Copy — Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, announced the formation of a Scientific Advisory Committee (SAC) to support the Company’s advancing clinical, regulatory, and commercialization strategy as it progresses toward late-stage development.
The SAC will provide independent, multidisciplinary expertise across clinical trial design, regulatory strategy, surgical application, lens science, and translational research. This will ensure strong clinical governance and informed decision making as Ocumetics prepares for pivotal clinical studies and future FDA engagement. Dr Ron Krueger, MD, MSE, a globally recognized ophthalmologist, surgeon, and innovator in refractive and cataract surgery, will be a member of the SAC.
Dr. Krueger brings decades of leadership in clinical research, surgical innovation, and technology translation, including extensive experience guiding ophthalmic devices through advanced clinical development. He is the McGraw Professor and Chairman of Ophthalmology at the University of Nebraska Medical Center. Previously, Dr. Krueger was on staff at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and a senior staff surgeon at the Cleveland Clinic Cole Eye Institute.
Dr. Krueger is internationally recognized for his pioneering contributions to laser vision correction, cataract surgery, and presbyopia treatment. He has authored more than 300 peer-reviewed publications, book chapters, and scientific presentations. Dr. Krueger has served as a principal investigator in numerous clinical trials and has advised multiple ophthalmic device companies on clinical development, regulatory strategy, and surgical adoption.
Dean Burns, President and CEO of Ocumetics, stated that Dr. Krueger’s scientific rigor, clinical insight, and experience translating innovation into clinical practice make him an ideal addition to the Scientific Advisory Committee. Burns added that the committee structure ensures that the company is drawing from the best collective expertise to guide its clinical execution and regulatory strategy as it enters a more complex phase of development.
The Scientific Advisory Committee will function as a strategic advisory body, providing guidance on:
- Clinical trial design and endpoint optimization
- First-in-human and pivotal study execution
- Regulatory strategy and FDA engagement
- Surgical usability and adoption considerations
- Risk assessment and clinical governance
- Commercialization readiness and physician education
Additional members of the SAC will be announced in the coming months. Ocumetics is focused on advancing its accommodating intraocular lens technology through clinical validation and regulatory milestones, with the goal of delivering innovative vision solutions to patients worldwide.
Ocumetics Technology Corp. is a Canadian research and product development company dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies through innovative research and development.
Ocumetics is in the first-in-human early feasibility study phase of a game-changing technology for the ophthalmic industry and has developed an intraocular lens that fits within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.
Source: Ocumetics Technology Corp.
